Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Syneron-Candela Launches new Breakthrough Products at the 22nd World Congress of Dermatology in Seoul, Korea to Provide Unprecedented Aesthetic Device Technology


News provided by

Syneron-Candela

24 May, 2011, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

YOKNEAM, Israel, May 24, 2011 /PRNewswire/ --

Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today during the opening of the World Congress of Dermatology the global launch of several new devices that confirm the company's continued efforts towards offering physicians and their patients best in class solutions for energy based aesthetic applications.

These new devices and their upgrades are being presented to international physicians for the first time at the Syneron-Candela booth during a medical meeting which takes place only once every four years and represents the premier global event for latest advancements in skin health organized under the auspices of the International League of Dermatological Societies.

"We are excited about the opportunity we have to share our latest innovations with the prominent scientific and medical professionals attending this meeting," said Louis P. Scafuri, Chief Executive Officer of Syneron. "The history of our company is steeped in science that offers results and is at the basis of the trust filled relationships we have developed with our medical partners over the years."

ePrime(TM)

This revolutionary facial treatment technology offers consumers with the best possible treatment option for improved skin volume, tightening, tone and elasticity. This minimally invasive aesthetic device can deliver deep into the dermis controlled amounts of Radio Frequency (RF) energy for dramatic improvements in skin appearance in just one single treatment. During the media panel, Henry Hin Lee Chan, MD, PhD - Hong Kong Dermatology and Laser Centre said that because this device "uniquely induces marked elastin, collagen and hyaluronic acid production, all naturally occurring substances that help define skin tone and texture, we are getting great improvement in facial skin treated by e-Prime. In addition, we are getting great feedback from clients on how thrilled they are by their natural and relaxed appearance and improved complexion."

GentleLASE(R) Pro

This is the company's latest and most advanced aesthetic laser. With this new device, physicians are able to treat much more than just unwanted hair as it also offers an opportunity to treat sun damaged skin, age spots, freckles and wrinkles. It is easy to use, cost effective, fast and provides unparalleled hair removal efficacy thanks to its delivery of the highest peak power in hair removal lasers. The enhanced versatility of this machine comes from various features including the variable pulse duration, possibility to choose between six different spot sizes, multiple hand pieces and light weight delivery systems that contribute to lower operator fatigue and greater treatment convenience.

On-going innovation

"Innovation is the main driver of our business. We are passionate about it and all the new ideas or improvements we bring to the market, are based on strong scientific data and our heavy investment in research and development," said Shimon Eckhouse, co-founder and Chairman of Syneron.

A clear illustration of Syneron's innovation and ability to bring new and exciting products and technology to the market are 3 products that have been launched just within the last 12 months - elure(TM), eMatrix(R) and CO2RE(TM).

elure is a revolutionary topical cosmetic for skin lightening which uses the proprietary patented natural enzyme, Melanozyme(TM). elure is the only skin whitening product in the world that lightens skin by decomposing melanin, the pigment that accumulates in the skin to cause a darkened or uneven skin tone. This unique mode of operation allows elure to create healthier, brighter and younger-looking skin in less than 30 days, with an excellent safety profile and very high tolerability.

eMatrix Sublative Rejuvenation(R) is the world's first bipolar RF technology for energy-based facial rejuvenation. Patient down time is minimal when adopting this treatment methodology thanks to the unique delivery of high-intensity dermal impact and minimal epidermal disruption. Physicians can comfortably use this device for all skin types and tones and in particular the darker skin colors that are often more difficult to treat.

CO2RE is a complete CO2 resurfacing system that offers physicians more choices and greater flexibility for meeting their individual practice needs. It includes a unique fusion fractional mode for treating superficial and deep skin layers simultaneously with precision control over the intensity pattern and depth of ablation.

All of Syneron's products are backed by scientific data which is regularly presented at high level medical meetings and conferences, highlighting the company's commitment to science. This unique combination of cutting edge science, life-enhancing clinical results and high level of trust within the global aesthetic community contributes to solidifying Syneron's leadership position in the Medical Aesthetic market.

About Syneron Medical Ltd.

In 2009, Syneron Medical Ltd. and Candela Corporation merged to create the global leader in the medical aesthetic devices market with both a short and long-term vision for developing this market. The strong financial base and aligned resources, allow this newly formed company to offer customers the broadest available product portfolio, the best global service organization and an expansive worldwide distribution network.

Media contacts:

Linda.pavy@bm.com - Tel. +33-141867626; Mobile: +33-607594395

sungeun.yoon@pharmaxogilvy.com -Tel. +82-2-513-1879; Mobile: +82-10-9322-2678

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.